What Happens Subsequently in AML When Cytogenetic Abnormalities Persist at Bone Marrow Harvest? Results of the 10th UK MRC AML Trial

Bone Marrow Transplantation - United Kingdom
doi 10.1038/sj.bmt.1700804
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Bone Marrow Microenvironment in the Pathogenesis of AML

2011English

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML

Frontiers in Oncology
Cancer ResearchOncology
2020English

Autologous Transplantation in 1st Cr Aml Patients With Purged or Unpurged Bone Marrow: Good Clinical Results in Favorable Cytogenetic Group and in Those Infused With a Low Number of Marrow Cells

Journal of Bone Marrow Research
2014English

TP53 Mutated AML Subclones Exhibit Engraftment in a Humanized Bone Marrow Ossicle Mouse Model

Annals of Hematology
MedicineHematology
2020English

The Results of Treatment in Children With AML and Initial Hyperleucocytosis According to the AML-MM-2006 Protocol

Pediatric Hematology/Oncology and Immunopathology
OncologyPediatricsChild HealthAllergyHematologyPerinatologyImmunology
2020English

What Happens to the Body When One Works at Night?

Cadernos de Saude Publica
MedicineEnvironmentalPublic HealthOccupational Health
2004English

Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

Advances in Hematology
Hematology
2012English

Detection of AML-specific TP53 Mutations in Bone Marrow–derived Mesenchymal Stromal Cells Cultured Under Hypoxia Conditions

Annals of Hematology
MedicineHematology
2019English

Allogeneic Hematopoietic Stem Cell Transplantation for Intermediate Cytogenetic Risk AML in First CR

Bone Marrow Transplantation
TransplantationHematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy